BRPI0708071A8 - Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos - Google Patents

Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos

Info

Publication number
BRPI0708071A8
BRPI0708071A8 BRPI0708071A BRPI0708071A BRPI0708071A8 BR PI0708071 A8 BRPI0708071 A8 BR PI0708071A8 BR PI0708071 A BRPI0708071 A BR PI0708071A BR PI0708071 A BRPI0708071 A BR PI0708071A BR PI0708071 A8 BRPI0708071 A8 BR PI0708071A8
Authority
BR
Brazil
Prior art keywords
compounds
catecholamine derivatives
deuterated catecholamine
drugs including
well
Prior art date
Application number
BRPI0708071A
Other languages
English (en)
Inventor
Alken Rudolf-Giesbert
Schneider Frank
Original Assignee
Birds Pharma Gmbh Berolina Innovative Res & Development Services
Imphar Ag
Ratiopharm Gmbh
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birds Pharma Gmbh Berolina Innovative Res & Development Services, Imphar Ag, Ratiopharm Gmbh, Teva Pharmaceuticals Int Gmbh filed Critical Birds Pharma Gmbh Berolina Innovative Res & Development Services
Publication of BRPI0708071A2 publication Critical patent/BRPI0708071A2/pt
Publication of BRPI0708071A8 publication Critical patent/BRPI0708071A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

DERIVADOS DE CATECOLAMINA DEUTERADA E MEDICAMENTOS COMPREENDENDO OS DITOS COMPOSTOS. A presente invenção refere-se a derivados de catecolamina deuterada, assim como a medicamentos contendo esses compostos. Em adição, a presente invenção refere-se ao uso de derivados de catecolamina deuterada, assim como os sais fisiologicamente aceitáveis dos mesmos, e também a composições farmacêuticas, que contêm estes compostos, também em combinação com inibidores de enzima, para o tratamento de doenças por deficiência de dopamina ou de doenças que se baseiem em transporte de tirosina interrompido ou tirosina descarboxilase interrompida, assim como de outros distúrbios.
BRPI0708071A 2006-02-17 2007-02-16 Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos BRPI0708071A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006008316 2006-02-17
DE102006008316.4 2006-02-17
PCT/EP2007/001555 WO2007093450A2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Publications (2)

Publication Number Publication Date
BRPI0708071A2 BRPI0708071A2 (pt) 2011-05-17
BRPI0708071A8 true BRPI0708071A8 (pt) 2017-12-26

Family

ID=38236462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708071A BRPI0708071A8 (pt) 2006-02-17 2007-02-16 Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos

Country Status (24)

Country Link
US (2) US8247603B2 (pt)
EP (2) EP1991522B1 (pt)
JP (1) JP5248331B2 (pt)
KR (1) KR101411422B1 (pt)
CN (1) CN101384545B (pt)
AU (1) AU2007214622B2 (pt)
BR (1) BRPI0708071A8 (pt)
CA (1) CA2642593C (pt)
CY (1) CY1117995T1 (pt)
DK (1) DK1991522T3 (pt)
EA (1) EA017983B1 (pt)
ES (1) ES2587368T3 (pt)
HR (1) HRP20161039T1 (pt)
HU (1) HUE028777T2 (pt)
IL (1) IL193102A (pt)
LT (1) LT1991522T (pt)
ME (1) ME02508B (pt)
PL (1) PL1991522T3 (pt)
PT (1) PT1991522T (pt)
RS (1) RS55142B1 (pt)
SI (1) SI1991522T1 (pt)
UA (1) UA97795C2 (pt)
WO (1) WO2007093450A2 (pt)
ZA (1) ZA200806568B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
EP2303330B2 (en) 2008-06-06 2021-06-16 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2897615A4 (en) 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9763904B2 (en) 2013-02-05 2017-09-19 Teva Pharmaceuticals International Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
KR20150115807A (ko) * 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
WO2014174425A2 (en) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions and methods for the treatment of orthostasis and neurological diseases
EA201600093A1 (ru) * 2013-07-08 2016-08-31 Ауспекс Фармасьютикалс, Инк. Дигидроксифенильные нейромедиаторные соединения, композиции и способы
JP2017503756A (ja) * 2013-11-22 2017-02-02 オースペックス ファーマシューティカルズ インコーポレイテッド 異常な筋活動を処置する方法
EP3424504A1 (en) 2013-12-03 2019-01-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
GB201420341D0 (en) * 2014-11-17 2014-12-31 Evolution Valves Ltd Valve arrangement
WO2016144901A1 (en) 2015-03-06 2016-09-15 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
CN106343013A (zh) * 2015-07-19 2017-01-25 中国科学院上海有机化学研究所 一种粮食储存方法
CN105360267B (zh) * 2015-10-09 2017-11-10 青岛振坤食品机械有限公司 一种全自动穿串机
WO2017060870A1 (en) 2015-10-09 2017-04-13 Hermann Russ Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
CN105862897B (zh) * 2016-04-11 2018-01-16 江苏省华建建设股份有限公司 砂质泥岩地基浅基础原槽浇筑施工工法
SG11202101817UA (en) 2018-09-13 2021-03-30 Univ Canberra Methods of inhibition
US12162902B2 (en) * 2018-12-06 2024-12-10 Sail Biomedicines Decarboxylase inhibitors for treating Parkinson's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
DE2049115C3 (de) 1970-10-06 1981-07-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokyo Verwendung von Calcium-5-butylpicolinat und/oder Calcium-5-pentylpicolinat bei der Bekämpfung des Parkinsonismus mit 3-(3,4-Dihydroxyphenyl)-L-alanin (L-Dopa)
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
DE10261808A1 (de) * 2002-12-19 2004-07-08 Turicum Drug Development Ag Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen

Also Published As

Publication number Publication date
KR101411422B1 (ko) 2014-07-03
EP3101001B1 (en) 2020-04-01
IL193102A0 (en) 2009-02-11
CY1117995T1 (el) 2017-05-17
US8247603B2 (en) 2012-08-21
BRPI0708071A2 (pt) 2011-05-17
RS55142B1 (sr) 2016-12-30
CA2642593A1 (en) 2007-08-23
CN101384545B (zh) 2014-09-03
CN101384545A (zh) 2009-03-11
CA2642593C (en) 2014-11-04
JP2009526799A (ja) 2009-07-23
US20090018191A1 (en) 2009-01-15
EP3101001A1 (en) 2016-12-07
USRE46555E1 (en) 2017-09-19
PT1991522T (pt) 2016-08-23
UA97795C2 (uk) 2012-03-26
HRP20161039T1 (hr) 2016-11-04
HUE028777T2 (en) 2017-01-30
AU2007214622A1 (en) 2007-08-23
DK1991522T3 (en) 2016-08-29
IL193102A (en) 2015-01-29
JP5248331B2 (ja) 2013-07-31
AU2007214622B2 (en) 2012-02-23
EP1991522A2 (en) 2008-11-19
ES2587368T3 (es) 2016-10-24
LT1991522T (lt) 2016-09-26
EA200801826A1 (ru) 2009-02-27
EA017983B1 (ru) 2013-04-30
KR20080106539A (ko) 2008-12-08
PL1991522T3 (pl) 2017-07-31
SI1991522T1 (sl) 2016-10-28
WO2007093450A2 (en) 2007-08-23
ME02508B (me) 2017-06-20
WO2007093450A3 (en) 2007-09-27
ZA200806568B (en) 2009-07-29
EP1991522B1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
BRPI0708071A8 (pt) Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112014008400A2 (pt) derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
BR112012006010A2 (pt) composto de glicina
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
EA200970022A1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
BRPI0513857A (pt) inibidores de hsp90
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH AND

B25A Requested transfer of rights approved

Owner name: IMPHAR AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements